# Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

Study · id `cardio:ct-nct01286558` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01286558](<https://clinicaltrials.gov/study/NCT01286558>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01286558

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

## Technical summary

Registry record NCT01286558. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2012-10-22.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 225 participants (enrolled count; ClinicalTrials.gov record NCT01286558, source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01286558, source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)
- Primary completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01286558, source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)
- Completion: Not reported
- Results first posted: 2012-10-22 (ClinicalTrials.gov record NCT01286558, source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01286558, source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01286558-2014-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
- Condition: Hypertension
- Intervention (Drug): 40 mg telmisartan
- Intervention (Drug): 5 mg amlodipine
- Intervention (Drug): 5 mg amlodipine
- Intervention (Drug): 80 mg telmisartan
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 1ff4ffc9d3e0ae8ee663b89fa0c4f4a5d33fb8ed413f99ef2ac5acda5523d247
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
